Evidence map›Paper›PMID 38449612›Full record

ArticleHeliyon2024

Trilobolide-6-O-isobutyrate exerts anti-tumor effects on cholangiocarcinoma cells through inhibiting JAK/STAT3 signaling pathway.

Hao-Xuan Zhang, Rui Fan, Qian-En Chen, Lin-Jun Zhang, Yang Hui, Peng Xu, Si-Yang Li, Guang-Ying Chen, Wen-Hao Chen, Dong-Yan Shen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hao-Xuan ZhangSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Rui FanSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Qian-En ChenSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Lin-Jun ZhangSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Yang HuiKey Laboratory of Tropical Medicinal Resource Chemistry of Ministry of Education, Hainan Normal University, Haikou, 570100, China.
Peng XuSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Si-Yang LiSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Guang-Ying ChenKey Laboratory of Tropical Medicinal Resource Chemistry of Ministry of Education, Hainan Normal University, Haikou, 570100, China.
Wen-Hao ChenKey Laboratory of Tropical Medicinal Resource Chemistry of Ministry of Education, Hainan Normal University, Haikou, 570100, China.
Dong-Yan ShenSchool of Medicine, Xiamen University, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
First Affiliated Hospital of Xiamen University · CNHainan Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trilobolide-6-O-isobutyrate exhibits significant antitumor effects on cholangiocarcinoma (CCA) cells by effectively inhibiting the JAK/STAT3 signaling pathway. This study aims to investigate the mechanisms underlying the antitumor properties of trilobolide-6-O-isobutyrate, and to explore its potential as a therapeutic agent for CCA. This study illustrates that trilobolide-6-O-isobutyrate efficiently suppresses CCA cell proliferation in a dose- and time-dependent manner. Furthermore, trilobolide-6-O-isobutyrate stimulates the production of reactive oxygen species, leading to oxidative stress and initiation of apoptosis via the activation of the mitochondrial pathway. Data from xenograft tumor assays in nude mice confirms that TBB inhibits tumor growth, and that there are no obvious toxic effects or side effects

Indexed as

ApoptosisCholangiocarcinomaJAK/STAT pathwayProliferationTBB

Identifiers

PMID38449612
PMCPMC10915568
OpenAlexW4392245799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.